Media coverage about Vital Therapies (NASDAQ:VTL) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vital Therapies earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.425303704516 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several equities analysts recently issued reports on the stock. BidaskClub raised shares of Vital Therapies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. Raymond James Financial reissued a “buy” rating on shares of Vital Therapies in a research report on Tuesday, December 5th. Zacks Investment Research lowered shares of Vital Therapies from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. Finally, ValuEngine raised shares of Vital Therapies from a “strong sell” rating to a “sell” rating in a report on Saturday, October 21st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $6.00.
Shares of Vital Therapies (VTL) traded down $0.15 during mid-day trading on Monday, reaching $6.00. 149,200 shares of the company’s stock traded hands, compared to its average volume of 141,844. The firm has a market cap of $253.24, a price-to-earnings ratio of -4.44 and a beta of 5.12. Vital Therapies has a 52 week low of $2.25 and a 52 week high of $6.70.
In other news, Director Muneer A. Satter bought 50,000 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were acquired at an average cost of $4.77 per share, with a total value of $238,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Muneer A. Satter bought 100,000 shares of Vital Therapies stock in a transaction on Wednesday, December 13th. The stock was acquired at an average price of $5.48 per share, with a total value of $548,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 300,000 shares of company stock worth $1,520,000 in the last ninety days. Corporate insiders own 32.60% of the company’s stock.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.